All drug pricing articles
-
BusinessDrug companies reluctantly accept state price negotiations
As legal challenges fall flat, will industry’s claims of stifled innovation be borne out?
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
BusinessFines upheld for Advanz Pharma over thyroid drug price increases
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
-
BusinessUS trade regulator sues to block Amgen–Horizon merger
Federal Trade Commission has concerns that union will allow Amgen to stifle potential competition for Horizon’s drugs
-
BusinessCalifornia advances plans to make its own insulin
Governor commits $100 million to develop low-cost insulin and build manufacturing facility to strengthen drug’s supply chain
-
OpinionThe price of failure
Drug market structures and high R&D failure rates can tempt companies into bad pricing behaviour
-
PodcastSofosbuvir
The hepatitis C drug that made waves when first launched – quicker to work and with fewer side effects than existing drugs, but it came with a hefty price tag
-
BusinessTrump lays out plan to slash drug costs
White House strategy to reduce pharmaceutical prices faces backlash from the industry, which cautions against the ‘far-reaching’ proposals
-
BusinessUS state passes law blocking generic drug price-gouging
Despite industry opposition, Maryland will be able to fine companies for ‘excessive and unjustified’ price increases
-
BusinessMylan settles Epipen overcharging allegations
Company will pay US Department of Justice $465m for avoiding paying rebates to government healthcare systems
-
BusinessUS supreme court limits patent rights
Biotech industry is concerned that ruling will hit small companies
-
OpinionDrug pricing must be more transparent
Pricing is a complex issue - how can we make it clearer?
-
BusinessEuropean Commission to investigate excessive drug pricing
Inquiry covers claims that Aspen Pharma’s price rises on five cancer treatments were unjustified
-
BusinessIndian drug industry opposes price caps
Government wants free healthcare for poorest people, but companies claim controls will stifle innovation
-
Business£90m fine for Pfizer and Flynn Pharma over excessive drug pricing
Markets watchdog imposes record fine for breaches of competition law
-
OpinionTime for better incentives to keep drug costs low
Getting outraged at drug price hikes is all very well, but we need more constructive options
-
OpinionForged in righteous flames
Could the debate over pharma price-gouging have positive results for both patients and companies?
-
Business
Pfizer agrees potential $785m fraud settlement
Whistleblower case relates to claims of Wyeth overcharging for acid reflux drugs between 2001 and 2006
-
Business
GSK fined for stalling antidepressant generics
UK Competition and Markets Authority deems pay-for-delay deal illegal and imposes £45m in fines
-
Business
Cancer Drugs Fund axes 23 treatments
The UK government has cut down the list of cancer therapies it will pay for through the Cancer Drugs Fund